Massive osteolysis

Gorham-Stout disease (GSD) is a rare, non-neoplastic disorder characterized by spontaneous, progressive osteolysis driven by proliferation of lymphatic and vascular channels within bone.[1][2] The International Society for the Study of Vascular Anomalies (ISSVA) classifies GSD as a complicated lymphatic anomaly, distinct from generalized lymphatic anomaly (GLA) and kaposiform lymphangiomatosis (KLA).[3] Pathogenesis involves a mechanistic triad of aberrant lymphangiogenesis, osteoclast hyperactivation, and immune dysregulation mediated through VEGF, IL-6, TNF-α, and the RANKL/RANK/OPG axis.[4][5][6] No causative germline mutation has been identified, though somatic variants in VEGF-family and EPHB4 genes have been reported.[7][8] The hallmark imaging pattern is progressive, relentless osteolysis with cortical destruction and no periosteal reaction.[2][9] The disease may be monostotic or polyostotic and can affect any bone; in the maxillofacial region the mandible is the predominant site.[10] Management is multimodal and individualized, combining medical therapy, radiotherapy, and surgery; no standardized protocol exists.[1][11]

• Current preferred name: Gorham-Stout disease (GSD). This is the designation used in the ISSVA 2018 classification of vascular anomalies.[3]
• Accepted synonyms: massive osteolysis, vanishing bone disease, disappearing bone disease, phantom bone disease.[12][13]
• Obsolete or imprecise terms: "invasive hemangiomatosis" and "lymphangiomatosis" have been applied historically but are discouraged; the former conflates the condition with hemangioma, and the latter is now reserved for GLA. The eponym "Gorham's disease" (without Stout) remains widely used and acceptable.[2][9]

GSD is exceedingly rare; approximately 400 cases had been documented through 2023.[1] There is a slight male predominance (male-to-female ratio roughly 1.5:1).[1] Onset spans all ages (reported range 0–77 years), but the majority of cases present in childhood, with roughly half manifesting before age 18.[1] The average delay from symptom onset to diagnosis is approximately 3.5 years.[1]

Any bone may be affected. The axial skeleton is involved more often than the appendicular skeleton, with the spine, ribs, and pelvis being the most common overall sites.[1] In the maxillofacial region, the mandible is by far the most frequently affected bone; maxillary involvement alone is uncommon.[10][14] Maxillary and/or mandibular destruction is found in nearly 20% of all GSD cases.[15] A systematic review of jaw-specific cases identified 24 mandibular, 12 combined mandible/maxilla/other, 3 both-jaw, and only 2 maxilla-only cases among 41 patients.[14]

Presentation and symptoms

• Pain is the most common symptom, reported in roughly two-thirds of patients.[1]
• Tooth mobility is a characteristic early sign when the jaws are involved and may mimic aggressive periodontal disease.[12]
• Swelling of the affected region is common; facial asymmetry develops as osteolysis progresses.[10]
• Pathologic fracture occurs in approximately one-third of maxillofacial cases and may be the event that prompts diagnosis.[10][12]
• A history of antecedent trauma is reported in about one-third of cases, though a causal relationship is unproven.[10][16]

Tempo

The disease is insidious and typically painless in early stages, allowing progressive bone destruction before clinical recognition.[12] The osteolytic process may advance over months to years; spontaneous arrest occurs occasionally but is unpredictable.[17][18]

Complications and red flags

• Extension across the midline of the mandible is associated with disease persistence after treatment.[10]
• Mandibular involvement may extend to the maxilla, temporal bone, zygoma, skull base, or cervical spine.[12][19]
• Chylothorax (when thoracic structures are involved) is the principal risk factor for mortality.[1][20]
• Cerebrospinal fluid leak and neurologic deficits may complicate skull or spinal involvement.[21]

Laboratory findings

Routine laboratory investigations are characteristically normal; markers of inflammation and standard bone turnover markers are typically not elevated.[11][12] Elevated serum IL-6 and VEGF-A have been reported in active disease and may serve as research biomarkers.[5][6] Alkaline phosphatase is mildly elevated in a minority of cases.[10]

Location and distribution in the jaws

The mandible is the characteristic site of maxillofacial involvement.[10][14] Within the mandible, the body and alveolar process are most commonly affected initially, with subsequent extension to the ramus, condyle, and contralateral side.[22][23] Isolated maxillary involvement is rare; when the maxilla is affected it is usually in conjunction with mandibular disease.[14] Polyostotic involvement of contiguous craniofacial bones (temporal bone, zygoma, skull base) occurs occasionally.[19]

Periphery and shape

• Osteolytic areas typically have poorly defined, irregular margins that lack a sclerotic border.[18][22]
• No periosteal reaction is present at the site of osteolysis, a characteristic negative finding that helps distinguish GSD from infection and malignancy.[2]
• In early stages, the margins may appear slightly more defined, resembling subcortical radiolucent foci, but they become increasingly indistinct as the disease progresses.[18][22]

Internal architecture

• The hallmark is progressive radiolucency replacing normal trabecular bone, beginning as patchy or mottled lucencies and advancing to complete loss of bony architecture.[12][18]
• Residual bone within the affected zone shows thinning and tapering of trabeculae, producing a "sucked-candy" or tapered appearance of remaining cortex.[12]
• No internal calcification, septation, or ground-glass density is present.[18]
• Generalized osteopenia of the affected bone and adjacent structures is common on plain radiography.[24]

Effects on teeth and the alveolar process

• Alveolar bone loss is a characteristic early finding when the jaws are involved and may closely mimic severe periodontal disease on panoramic radiograph, with infrabony defects and horizontal bone loss.[12]
• Progressive loss of alveolar support leads to tooth mobility and eventual spontaneous exfoliation.[12]
• Root resorption of involved teeth is not a prominent feature; teeth tend to lose their bony support and "float" rather than undergo external resorption.[12]
• Teeth extracted from affected areas may be attached only to marginal gingiva, with complete absence of underlying alveolar and basal bone.[12]

Cortical involvement and extent

• Cortical destruction is the defining radiographic criterion that distinguishes GSD from GLA, in which lytic areas remain confined to the medullary cavity.[9][25]
• Progressive cortical resorption leads to thinning, discontinuity, and eventual complete disappearance of cortical bone.[18][25]
• In advanced mandibular disease, the inferior cortex becomes extremely tapered and may fracture pathologically.[12]
• The osteolytic process does not respect anatomic boundaries: it may cross suture lines, extend across the midline, and involve contiguous bones.[10][19]
• CBCT and medical CT demonstrate the three-dimensional extent of cortical loss and can reveal early cortical erosion not visible on panoramic radiography.[12][19]

Growth pattern

• The process is centrifugal and relentless, expanding outward from the initial focus without respect for cortical barriers, joint spaces, or suture lines.[12][13]
• Serial imaging characteristically shows progressive enlargement of the osteolytic zone over months to years.[11][22]
• Spontaneous stabilization occurs occasionally but cannot be predicted radiographically.[17]

Recognized variants

• Monostotic disease (a single bone affected) accounts for roughly one-quarter of cases; polyostotic involvement (multiple contiguous bones) is more common.[1][20]
• In the jaws, lesions may be classified by radiographic extent as large (involving the majority of the mandibular body or ramus) or small (localized); however, lesion size does not significantly predict recurrence.[14]

Medical CT

CT demonstrates the full extent of osteolysis, including cortical destruction, residual bone tapering, and soft-tissue atrophy in the involved region.[12][19] Three-dimensional CT reconstructions are particularly useful for surgical planning and for documenting the extent of bone loss in complex craniofacial cases.[12] Contrast-enhanced CT may reveal adjacent soft-tissue lymphatic or vascular channels and is advocated for differential diagnosis.[19]

MRI

MRI is essential for characterizing the soft-tissue component and extent of lymphatic proliferation.[11][24] Affected bone marrow typically shows altered signal intensity; infiltrative soft-tissue abnormality adjacent to osseous lesions is common in GSD and significantly more frequent than in GLA.[25] Contrast-enhanced MRI may demonstrate lymphangiogenic invasion of bone, supporting the diagnosis.[11] MRI is the preferred modality for monitoring disease progression in soft tissues.[26]

Nuclear medicine

Technetium-99m bone scintigraphy may show increased uptake in the affected region during active osteolysis, confirming the metabolically active nature of the process; it is also useful for excluding additional skeletal sites.[12] DEXA scanning can confirm the monostotic or polyostotic nature of disease and document regional bone density loss.[12]

Massive osteolysis of the jaws requires differentiation from other conditions that produce progressive bone destruction without obvious mass formation. The absence of periosteal reaction, the lack of a soft-tissue mass, and the relentless progressive nature of osteolysis are the key features guiding differential reasoning.

The highest-risk diagnostic pitfall is misdiagnosis as aggressive periodontal disease when GSD initially presents with alveolar bone loss and tooth mobility in the mandible.[12] Any case of rapidly progressive, unexplained alveolar bone loss—particularly in a young patient with normal inflammatory markers—warrants biopsy and cross-sectional imaging to exclude GSD before attributing the findings to periodontitis.

Diagnostic microscopic findings

• The hallmark is non-neoplastic proliferation of thin-walled vascular and lymphatic channels within bone, lined by a single layer of flattened endothelial cells without cellular atypia.[16][18]
• Surrounding stroma consists of fibrovascular connective tissue with scattered lymphocytes, plasma cells, and active fibroblasts; there is no evidence of inflammation, infection, or malignancy.[12][16]
• Increased osteoclast number and enlarged osteocyte lacunae are present in affected bone.[5]
• Progressive replacement of bone by fibrous tissue and vascular channels leads to thinning and disappearance of bony trabeculae.[18]

Immunohistochemistry

• Endothelial cells lining the proliferative channels are positive for D2-40 (podoplanin) and PROX-1, confirming lymphatic differentiation.[20][21]
• Vascular markers CD31 and CD34 are also positive, reflecting the mixed lymphatic-vascular nature of the proliferation.[20]
• Mild expression of VEGF and VEGFR-3 has been demonstrated in affected tissue.[20]

Radiologic-pathologic correlation

The progressive radiolucency on imaging corresponds to replacement of mineralized bone by proliferating lymphatic channels and fibrous tissue. The absence of periosteal reaction correlates with the non-inflammatory, non-neoplastic nature of the process. The cortical destruction that defines GSD radiographically reflects direct invasion and replacement of cortical bone by lymphatic channels, distinguishing it from GLA where channels remain within the medullary space.[9][25]

Workup and referral

GSD is a diagnosis of exclusion. Initial workup includes comprehensive laboratory studies (serum calcium, PTH, alkaline phosphatase, inflammatory markers, bone turnover markers) to exclude metabolic and endocrine causes; these are characteristically normal.[11][12] Cross-sectional imaging (CT and MRI) is essential for defining extent. Biopsy of the osteolytic region is required for definitive diagnosis.[10][12] Multidisciplinary referral to a vascular anomalies center or team experienced with complex lymphatic anomalies is recommended.[3]

Treatment

No standardized treatment protocol exists; management is individualized and multimodal.[1][11]

• Bisphosphonates (e.g., zoledronic acid, pamidronate, alendronate) are the most widely used medical therapy, employed in over half of reported cases, and can stabilize osteolysis.[1][12][20]
• Radiotherapy at moderate doses (40–45 Gy in conventional fractionation) achieves disease stabilization in approximately 77–80% of cases and is the only treatment significantly associated with disease remission in maxillomandibular GSD. Lower doses (16–20 Gy) have been used successfully in thoracic disease.[15][17][28][29]
• Sirolimus (mTOR inhibitor) has emerged as an effective systemic agent that stabilizes or reduces disease signs and symptoms.